DCAL Q4 FY26 Results & Earnings Analysis
Sentiment: Good (Confidence: medium)
Earnings Summary
Dishman Carbogen Amcis reported a strong Q4 FY26 with 19% YoY revenue growth (INR 851 crores) and full-year EBITDA margin expansion of 200 bps to 19.3%. Growth was driven by CDMO (+21%) and high-margin Vitamin D analogs. Key catalysts include ADC molecule supply (CHF 30-40M expected), tech transfer of a CHF 20-25M product to India (improving margins), and a new ECB loan to reduce high-cost debt. However, near-term caution is warranted due to geopolitical uncertainties, time-to-conversion of projects, and the French subsidiary's losses (targeting profitability by FY28). The company targets a 15% revenue CAGR and 25% EBITDA margin by FY28.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted a landmark quarter with revenue of INR 851 crores, strong performance in CDMO and Vitamin D analogs, and a 200 bps improvement in full-year EBITDA margins. Management expressed confidence in the strategy and future growth.
- Q&A Session: Neutral — Analyst questions focused on debt reduction, India scale-up timelines, margin trajectory, and the French subsidiary's losses. Management's responses were detailed but cautious on guidance, noting delays in France and the need to wait for more clarity on revenue and margin targets.
Revenue Growth Drivers
- Strong Q4 performance driven by CDMO (+21%) and Vitamin D analogs.
- ADC molecule supply growth with purchase orders in hand.
- Tech transfer of a CHF 20-25 million product from Switzerland to India.
Growth vs Margin Focus
Management targets a 25% EBITDA margin by FY28 while aiming for a 15% revenue CAGR, indicating a balanced focus on growth and profitability.
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited (DCAL) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.